New Approaches in Glioblastoma Multiforme: The Potential Role of Immune- check Point Inhibitors

Author(s): Francesca De Felice, Daniela Musio, Raffaele Cassese, Giovanni Luca Gravina, Vincenzo Tombolini

Journal Name: Current Cancer Drug Targets

Volume 17 , Issue 3 , 2017

  Journal Home
Translate in Chinese
Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Background: Glioblastoma multiforme (GBM) is the most frequent brain tumor. Despite recent advances in treatment approaches the prognosis remains poor, with a median overall survival of 14.6 months. Immunotherapy is the subject of ongoing research and its benefit is becoming evident in other malignancies. Immune check-points such as cytotoxic T lymphocyte associated antigen 4 (CTLA-4), programmed cell death receptor (PD-1) and indoleamine 2,3-dioxygenase (IDO) reduce immune response.

Objective: To clarify the role of immune check point inhibitors in GBM management.

Methods: Preclinical and clinical trials of immune check-point inhibitors in GBM were obtained by searching for English peer-reviewed articles on PubMed databases, trials registered on clincaltrials. gov and abstracts recently presented at international congresses.

Results: Immune check point inhibitors may be of critical importance for the design of future immunotherapy approaches in GBM management.

Conclusion: Immune check-point inhibitors should be considered a promising treatment option in GBM.

Keywords: Immunotherapy, glioblastoma multiforme, check-point, radiotherapy, PD-1, CTLA-4, ipilimumab, immune system.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2017
Published on: 31 January, 2017
Page: [282 - 289]
Pages: 8
DOI: 10.2174/1568009616666160813183738
Price: $65

Article Metrics

PDF: 67